Core Points - Exagen Inc. will release its financial results for the quarter ended June 30, 2024, on August 5, 2024, before market opens [1] - The conference call to discuss the results will be hosted by John Aballi, President and CEO, and Kamal Adawi, CFO, at 8:30 AM ET [1] - Exagen is a leading provider of autoimmune testing, aiming to improve clinical outcomes for patients with autoimmune diseases [2] Company Information - Exagen is located in San Diego County, California [2] - Interested parties can access the conference call via phone or webcast, with specific numbers and links provided [3] - A replay of the conference call will be available until August 19, 2024, with access details included [6]

Exagen, Inc. (NASDAQ:XGN) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Operator Greetings, welcome to Exagen, Inc. First Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of Incorporation or Organization) 1261 Lib ...

[Exagen Inc. First Quarter 2024 Financial Results](index=1&type=section&id=Exagen%20Inc.%20First%20Quarter%202024%20Financial%20Results) [First Quarter 2024 Highlights & CEO Commentary](index=1&type=section&id=First%20Quarter%202024%20Highlights%20%26%20CEO%20Commentary) The company reported strong Q1 2024 results with significant revenue growth and improved margins, raising full-year guidance Q1 2024 Key Metrics vs. Q1 2023 | Metric | Q1 2024 | Q1 2023 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $14.4 million | $11.2 million | +28.4% | | Gross Margin | 59.6% | 47.2% | +12.4 p.p. | | AVISE® CTD TTM ASP | $377 | - | +35.1% | | Net Loss | $(3.4) million | $(7.7) million | +56.3% Improvement | | Adjusted EBITDA | $(2.0) million | $(6.2) million | +67.7% Improvement | | Cash and Cash Equivalents | $27.3 million | - | - | - CEO John Aballi highlighted strong momentum carrying into the second quarter, driven by **increased volume and improved ASP**[3](index=3&type=chunk) - The company plans to enhance its flagship product, AVISE® CTD, which is **expected to increase its value to clinicians** and benefit financials[3](index=3&type=chunk) - The company's cash runway is **expected to last into 2026**[4](index=4&type=chunk) [First Quarter 2024 Financial Performance](index=1&type=section&id=First%20Quarter%202024%20Financial%20Performance) Revenue grew 28.4% and net loss was substantially reduced, driven by higher ASP and lower operating expenses Q1 2024 vs Q1 2023 Financial Results | Financial Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Revenue | $14.4 million | $11.2 million | | Gross Margin | 59.6% | 47.2% | | Operating Expenses | $17.4 million | $18.9 million | | Net Loss | $(3.4) million | $(7.7) million | | Adjusted EBITDA | $(2.0) million | $(6.2) million | - The increase in revenue and gross margin was primarily driven by an **improvement in the Average Selling Price (ASP)**[4](index=4&type=chunk)[5](index=5&type=chunk) - Operating expenses decreased due to **lower selling, general and administrative expenses** related to a reduced headcount[5](index=5&type=chunk) - As of March 31, 2024, the company held **$27.3 million in cash** and cash equivalents and had an accounts receivable balance of $10.9 million[6](index=6&type=chunk) [Full Year 2024 Guidance](index=2&type=section&id=Full%20Year%202024%20Guidance) The company raised its full-year 2024 guidance for revenue and adjusted EBITDA following strong Q1 performance Updated Full Year 2024 Guidance | Metric | Updated Guidance | | :--- | :--- | | Revenue | At least $55 million | | Adjusted EBITDA | Better than $(18) million | - The company believes its existing cash and cash equivalents are **adequate to meet anticipated cash requirements into 2026**[7](index=7&type=chunk) [Conference Call Information](index=2&type=section&id=Conference%20Call%20Information) A conference call was held on May 13, 2024, to discuss Q1 results, with replay information available - A conference call to review Q1 2024 results was scheduled for **May 13, 2024**, at 8:30 AM Eastern Time[8](index=8&type=chunk) - A replay of the conference call is **available until May 27, 2024**, with access details provided in the report[9](index=9&type=chunk) [Appendix: Financial Statements & Disclosures](index=2&type=section&id=Appendix%3A%20Financial%20Statements%20%26%20Disclosures) This section contains detailed unaudited financial statements, non-GAAP reconciliations, and forward-looking statement disclosures [Unaudited Condensed Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Statements%20of%20Operations) Statements of Operations (in thousands, except per share data) | | Three Months Ended March 31, | | | :--- | :--- | :--- | | | **2024** | **2023** | | **Revenue** | **$14,415** | **$11,230** | | Costs of revenue | $5,817 | $5,926 | | Selling, general and administrative expenses | $10,542 | $11,884 | | Research and development expenses | $1,059 | $1,126 | | **Total operating expenses** | **$17,418** | **$18,936** | | **Loss from operations** | **$(3,003)** | **$(7,706)** | | **Net loss** | **$(3,360)** | **$(7,688)** | | **Net loss per share, basic and diluted** | **$(0.19)** | **$(0.44)** | [Unaudited Condensed Balance Sheets](index=6&type=section&id=Unaudited%20Condensed%20Balance%20Sheets) Condensed Balance Sheets (in thousands) | | **March 31, 2024** | **December 31, 2023** | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $27,267 | $36,493 | | Accounts receivable, net | $10,901 | $6,551 | | **Total current assets** | **$42,400** | **$47,841** | | **Total assets** | **$50,808** | **$56,944** | | **Liabilities and Stockholders' Equity** | | | | **Total current liabilities** | **$8,783** | **$11,902** | | **Total liabilities** | **$30,817** | **$34,250** | | **Total stockholders' equity** | **$19,991** | **$22,694** | | **Total liabilities and stockholders' equity** | **$50,808** | **$56,944** | [Reconciliation of Non-GAAP Financial Measures](index=7&type=section&id=Reconciliation%20of%20Non-GAAP%20Financial%20Measures) Reconciliation of Net Loss to Adjusted EBITDA (in thousands) | | Three Months Ended March 31, | | | :--- | :--- | :--- | | | **2024** | **2023** | | **Net loss** | **$(3,360)** | **$(7,688)** | | Other (Income) Expense | $(192) | $(656) | | Interest Expense | $549 | $638 | | Depreciation and amortization expense | $458 | $553 | | Stock-based compensation expense | $553 | $984 | | **Adjusted EBITDA (Non-GAAP)** | **$(1,992)** | **$(6,169)** | [Use of Non-GAAP Financial Measures and Forward-Looking Statements](index=2&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures%20and%20Forward-Looking%20Statements) - The company uses **adjusted EBITDA**, a non-GAAP measure, which it defines as net loss excluding certain non-cash and other items[10](index=10&type=chunk) - The company cautions that **forward-looking statements are subject to risks and uncertainties** inherent in the business[16](index=16&type=chunk)[17](index=17&type=chunk)

Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Conference Call March 18, 2024 8:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Mark Massaro - BTIG Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to Exagen Inc.’s Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions] At this time, I’ll hand the conference over to Ryan Dou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or other jurisdiction of incorpor ...

Financial Data and Key Metrics Changes - For Q3 2023, total revenues were $13.4 million, down from $14.1 million in Q2 2023 and $14.7 million in Q3 2022 [27] - The trailing 12-month average selling price (ASP) for AVISE CTD testing increased from $279 at the start of the year to over $320 in Q3, reflecting a $40 increase [11] - Adjusted EBITDA for the first three quarters of 2023 was negative $13.2 million, significantly improved from negative $26.4 million in the same period of 2022 [15][30] - The net loss for Q3 2023 was $5.4 million, compared to a net loss of $8.1 million in Q3 2022 [29] Business Line Data and Key Metrics Changes - AVISE CTD testing volumes were 32,618 in Q3 2023, reflecting a decline in test volume [27][18] - Other testing revenue was $1.4 million in Q3 2023, down from $1.6 million in Q2 2023 and $1.9 million in Q3 2022 [27] Market Data and Key Metrics Changes - The company experienced a modest decline in test volume in Q3, attributed to changes in ordering patterns rather than a contraction in the physician base [18][19] - The accounts receivable balance at the end of Q3 was $17 million, which improved to approximately $11.6 million by October 31 [16][32] Company Strategy and Development Direction - The company is focusing on higher-margin products and implementing changes to expand margins while controlling costs [9][10] - A significant milestone was achieved with an exclusive license agreement with Johns Hopkins University to develop clinical tests for lupus nephritis [21][22] - The strategy remains centered on improving AVISE CTD ASP and pursuing more profitable business [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to prior volume levels in the latter half of 2024, with Q4 expected to be the low point due to seasonality and recent changes [20][40] - The company anticipates finishing 2023 with more than $30 million in cash, providing sufficient funds to execute its operating strategy into late 2025 or early 2026 [17][87] Other Important Information - The company finalized a settlement with the Department of Justice for $650,000 related to past activities [25] - Management is closely monitoring proposed FDA regulations for lab-developed tests, believing AVISE CTD is well-positioned to comply [24] Q&A Session Summary Question: What is the reason for the decline in test volume? - Management indicated that the decline is due to changes in the billing process and adjustments by clinicians, not a reduction in the physician base [34][36] Question: Were there any one-time impacts in the quarter? - Management confirmed that $600,000 collected from prior period tests contributed to the quarter's performance, but this is not considered a one-time event [44][47] Question: What is the outlook for cash flow and working capital in 2024? - Management expects to see continued improvement in cash collections and a decrease in accounts receivable, indicating a positive trend into early next year [52][73] Question: What is the status of the Noridian LCD request? - The company remains in a holding pattern regarding the Noridian LCD request, awaiting further developments [66] Question: How is the company evaluating the success of the Johns Hopkins agreement? - Management emphasized the importance of developing clinically meaningful technology and expects to see progress in the next 24 months [94][96]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of Incorporation or Organization) 1261 ...

Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi - CFO Ryan Douglas - IR Conference Call Participants Dan Brennan - TD Cowen Mark Massaro - BTIG Dustin Scaringe - William Blair Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Operator Greetings. Welcome to the Exagen Inc. Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will foll ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of Incorporation or Organization) 1261 Libe ...